Skip to content
| Year | |
|---|---|
| Article |
Javan Balegh Marand A, et al. Differences in the Urinary Microbiome of Patients with Overactive Bladder Syndrome with and without Detrusor Overactivity on Urodynamic Measurements. |
| Year | |
|---|---|
| Article |
Damgaard, R, et al. HPV type-specific likelihood of regression in women undergoing active surveillance for CIN2 HPV16. |
| Year | |
|---|---|
| Article |
Evans T, et al. Assessment of CD8+ T-cell mediated immunity in an influenza A/H3N2 human |
| Year | |
|---|---|
| Article |
Aitken CA, et al. Sociodemographic Characteristics and Screening Outcomes of Women |
| Year | |
|---|---|
| Article |
Armando F, et al. SARS-CoV-2 Omicron variant causes mild pathology in the upper and |
| Year | |
|---|---|
| Article |
Mykytyn AZ, et al. Antigenic mapping of emerging SARS-CoV-2 omicron |
| Year | |
|---|---|
| Article |
D’Souza G, et al. Prevalence of oral and blood oncogenic human papillomavirus biomarkers among an enriched screening population: Baseline results of the MOUTH study. |
| Year | |
|---|---|
| Article |
Vink FJ, et al. FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 |
| Year | |
|---|---|
| Article |
Prins MLM, et al. Viral clearance, pharmacokinetics and tolerability of |
| Year | |
|---|---|
| Article |
Somogyi E, et al. T cell immunity ameliorates COVID-19 disease severity and provides post-exposure prophylaxis after peptide-vaccination, in Syrian hamsters. |
| Year | |
|---|---|
| Article |
Aknouch I, et al. Human milk inhibits some enveloped virus infections, |
| Year | |
|---|---|
| Article |
Armando F, et al. SARS-CoV-2 Omicron variant causes mild pathology |
| Year | |
|---|---|
| Article |
Bibby DC, et al. Interlaboratory Reproducibility of Standardized Hemagglutination Inhibition Assays. |
| Year | |
|---|---|
| Article |
Damgaard RK, et al. Performance of HPV E4 and p16INK4a biomarkers in predicting regression of cervical intraepithelial neoplasia grade 2 |
| Year | |
|---|---|
| Article |
de Geus V, et al. Identifying Molecular Changes in Early Cervical Cancer |
| Year | |
|---|---|
| Article |
Du W, et al. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern. |
| Year | |
|---|---|
| Article |
Ghorzang E, et al. HPV type-specific distribution among family members |
| Year | |
|---|---|
| Article |
Hammer A, et al. Evidence of latent HPV infection in older Danish |
| Year | |
|---|---|
| Article |
King CHS 4th, et al. Communicating regulatory high-throughput |
| Year | |
|---|---|
| Article |
Mena M, et al. Concordance of p16<sup>INK4a</sup> and E6*I mRNA among HPV-DNA-Positive Oropharyngeal, Laryngeal, and Oral Cavity Carcinomas |
| Year | |
|---|---|
| Article |
Pagan L, et al. Results of a randomized, placebo-controlled, first-in-human |
| Year | |
|---|---|
| Article |
Pedersen H, et al. Clinical Performanceof the Full Genotyping Agena MassARRAY HPV Assay Using SurePath Screening Samples within the VALGENT4 |
| Year | |
|---|---|
| Article |
Sierra MS, et al. Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial. |
| Year | |
|---|---|
| Article |
Tewari SR, et al. Association of Plasma Circulating Tumor HPV DNA With HPV-Related Oropharynx Cancer. JAMA Otolaryngol Head Neck Surg. |
| Year | |
|---|---|
| Article |
van den Tweel MM, et al. The relationship between vaginal pH and bacterial vaginosis as diagnosed using qPCR in an asymptomatic subfertile population. |
| Year | |
|---|---|
| Article |
Verhoef L, et al. Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV-positive women: |
| Year | |
|---|---|
| Article |
Wahid R, et al. Evaluating stability of attenuated Sabin and two novel |
| Year | |
|---|---|
| Article |
Wahid R, et al. Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines |
| Year | |
|---|---|
| Article |
Zarn KE, et al. Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants. |
| Year | |
|---|---|
| Article |
Zwittink RD, et al. The vaginal microbiota in the course of bacterial vaginosis treatment. |
| Year | |
|---|---|
| Article |
Du W, et al. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern. |
| Year | |
|---|---|
| Article |
Bibby DC, et al. Interlaboratory Reproducibility of Standardized Hemagglutination Inhibition Assays. |
| Year | |
|---|---|
| Article |
Armando F, et al. SARS-CoV-2 Omicron variant causes mild pathology |
| Year | |
|---|---|
| Article |
Hu SY, et al.Performance of Cervical Screening a Decade Following |
| Year | |
|---|---|
| Article |
Cabanski M, et al. Identifying Molecular Changes in Early Cervical Cancer Flow cytometric method transfer: Recommendations for best practice. |
| Year | |
|---|---|
| Article |
Bhatia R, et al. Evaluation of HarmoniaHPV test for detection of clinically significant Human Papillomavirus infection using the VALGENT framework. |
| Year | |
|---|---|
| Article |
Bonde J, et al. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study. |
| Year | |
|---|---|
| Article |
Dasgupta S, et al. Relationship of human papillomavirus with seborrheic keratosis of the female genital tract – a case-series and literature review. |
| Year | |
|---|---|
| Article | |
| Year | |
|---|---|
| Article |
Liu Y, et al. Transient CRISPR-Cas Treatment Can Prevent Reactivation of |
| Year | |
|---|---|
| Article |
Watterson D, et al. Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. |
| Year | |
|---|---|
| Article |
McMillan CLD, et al. Development of molecular clamp stabilized hemagglutinin |
| Year | |
|---|---|
| Article |
Ryu DK, et al. The in vitro and in vivo efficacy of CT-P59 against Gamma, |
| Year | |
|---|---|
| Article |
Shim TN, et al. The prevalence of human leucocyte antigen and human papillomavirus DNA in penile intraepithelial neoplasia in England 2011-2012. |
| Year | |
|---|---|
| Article |
Sierra MS, et al. Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated |
| Year | |
|---|---|
| Article |
Tota JE, et al. Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the |
| Year | |
|---|---|
| Article |
van den Munckhof EHA, et al. Developing an algorithm for the diagnosis of abnormal vaginal |
| Year | |
|---|---|
| Article |
men by immunohistochemical markers p16, Ki-67, HPV-E4 and DNA methylation markers. |
| Year | |
|---|---|
| Article |
van der Zee RP, et al. Cancer Risk Stratification of Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus-Positive Men by Validated Methylation |
| Year | |
|---|---|
| Article |
Vos LMet al. Lower respiratory tract infection in the community: |
| Year | |
|---|---|
| Article |
McMillan CLD, et al. Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses. |
| Year | |
|---|---|
| Article |
Watchorn RE, et al. Balanopreputial sac and urine microbiota in |
| Year | |
|---|---|
| Article |
Zwittink RD, et al. The vaginal microbiota in the course of bacterial vaginosis treatment. |
| Year | |
|---|---|
| Article |
Mykytyn AZ, Let al. Susceptibility of rabbits to SARS-CoV-2. |
| Year | |
|---|---|
| Article |
Ryu DK, Song Ret al. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. |
| Year | |
|---|---|
| Article |
Wahid R, et al. Assessment of genetic changes and neurovirulence of |
| Year | |
|---|---|
| Article |
Stadlbauer D, et al. AS03-adjuvanted H7N9 inactivated split virion vaccines |
| Year | |
|---|---|
| Article |
Konz JO, et al. Evaluation and validation of next-generation sequencing to support lot release for a novel type 2 oral poliovirus vaccine. |
| Year | |
|---|---|
| Article |
van der Lubbe JEM, et al. Ad26.COV2.S protects Syrian hamsters against G614 spike variant |
| Year | |
|---|---|
| Article |
Watterson D, et al. Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. |
| Year | |
|---|---|
| Article |
van Keulen BJ, et al. Human Milk from Previously COVID-19-Infected Mothers: The Effect of Pasteurization on Specific Antibodies and Neutralization Capacity. |
Reach out to our experts and see how we can help advance your clinical trial
Contact Us